Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology and antiviral drug candidates, with its lead program centered on Annamycin, a liposomal anthracycline designed to avoid the cardiotoxicity associated with older drugs in the class. The company also advances WP1066 and related formulations through investigator-initiated and preclinical studies, while relying heavily on intellectual property, sponsored research, and external clinical partners rather than commercial sales.

1.41

1.41

— Moleculin Biotech, Inc.
%
Lead oncology candidate0% Annamycin is the company's main drug program, aimed at treating cancers with a non-cardiotoxic anthracycline approach.
Additional oncology programs0% WP1066 oral and IV formulations are being developed for brain cancer and other oncology settings.
Antiviral and adjacent technologies0% WP1122-related assets and options cover potential antiviral and other therapeutic applications.
Intellectual property and licensing0% Patent filings, licenses, and sponsored research agreements support exclusivity and development rights.

Moleculin does not sell commercial products today; its primary counterparties are clinical investigators, research...

  • Academic and clinical research partnersprimary

    Universities and cancer centers buy or receive study drug and collaborate on trials to generate efficacy and safety data.

  • Future oncology treatment providersemerging

    Hospitals and oncologists would use approved Annamycin or related therapies in cancer care settings.

  • Patients with high-unmet-need cancersprimary

    Patients are the end beneficiaries for Annamycin and WP1066 programs targeting difficult-to-treat cancers.

  • Licensing and development counterpartiessecondary

    Partners such as MD Anderson are important for IP access, sponsored research, and option structures.

Moleculin is headquartered in the United States and its development activities are centered around U.S...

  • •United States is the operational base and main clinical-development hub
  • •Houston, Texas is important through MD Anderson-originated IP
  • •Northwestern University supports U.S. investigator-initiated clinical work
  • •Emory University supports U.S. preclinical formulation studies
  • •Europe and other jurisdictions matter for Annamycin patent exclusivity

The company is concentrating resources on Annamycin and away from non-core WP1122 licenses, reflecting a tighter...

01
Advance Annamycin through clinical and regulatory milestonesshort-term

Annamycin is the lead value driver and the most advanced program in the portfolio.

02
Protect global intellectual propertymedium-term

Patent exclusivity is critical for future commercialization and partnering value.

03
Use external research partnerships to conserve cashshort-term

The company has limited resources and relies on collaborators to progress programs efficiently.

Moleculin remains a development-stage biotech with no product revenue, so its value depends on successful clinical...

high

Nasdaq delisting risk

The company disclosed non-compliance with equity and bid-price requirements.

Scope
Common stock liquidity, financing access, and investor base
Materiality
high
high

Financing and dilution risk

The company expects to need additional capital and has warrant-related dilution exposure.

Scope
Share count, ownership dilution, and valuation pressure
Materiality
high
high

Clinical development risk

Drug candidates may fail to show sufficient safety or efficacy in trials.

Scope
Annamycin, WP1066, and related formulations
Materiality
high
medium

Regulatory risk

FDA feedback and approval requirements can delay or alter development plans.

Scope
Trial design, safety monitoring, and eventual approval path
Materiality
high
medium

IP and collaboration dependency

The business relies on licensed technology and external research partners.

Scope
MD Anderson licenses, sponsored research, patent scope
Materiality
medium
Warrant accounting
Non-cash gains/losses and equity presentation
Fair value measurement of warrants
Other income/expense and earnings volatility
R&D expense recognition
Operating loss and cash burn
Going-concern and liquidity assumptions
Disclosure sensitivity and capital structure analysis

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

BeyondSpring Inc.

BYSI · Pharmaceutical Preparations

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Annexon, Inc.

ANNX · Pharmaceutical Preparations

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

: 28/04/2026